Sera Prognostics (SERA) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
18 May, 2026Unmet need and clinical opportunity
Preterm birth affects 1 in 10 pregnancies, representing a significant and common healthcare challenge with few effective screening options.
Premature births lead to substantial long-term health complications and societal costs, with lifetime healthcare expenses for preterm individuals estimated to be 50x to 300x higher than those born full term.
PRIME trial results and feedback
The PRIME trial, a 5,000-person randomized controlled study, showed a 20% reduction in NICU admissions and a 56% reduction in births before 32 weeks using a bundled intervention.
The intervention bundle (aspirin, progesterone, nurse calls) is low-cost, low-risk, and has received positive feedback from clinicians for both clinical and economic impact.
Neonatal morbidity and mortality were reduced by 20%, with significant reductions in both NICU admissions and days, resonating strongly with neonatologists.
Health economics and payer engagement
Number needed to screen is 4.2 to save one NICU day, and 40 to prevent one NICU admission, which is nearly four times better than current standards.
Payers quickly recognize the economic value, especially given the high costs associated with NICU stays.
Latest events from Sera Prognostics
- Director nominee resignation leads to a reduced board; proxy votes for him will not be counted.SERA
Proxy filing1 Jun 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation8 May 2026 - Net loss of $8.4M and $14,000 revenue, with cash runway extended through 2029.SERA
Q1 20267 May 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving neonatal outcomes and reducing costs.SERA
Corporate presentation6 May 2026 - Director elections, auditor ratification, and ESG priorities highlight this year's proxy.SERA
Proxy filing24 Apr 2026 - Vote on director elections and auditor ratification at the June 2026 virtual annual meeting.SERA
Proxy filing24 Apr 2026 - PRIME study validated efficacy, commercial expansion advanced, and cash runway secured.SERA
Q4 202518 Mar 2026 - PreTRM enables early, validated prediction of preterm birth, reducing NICU admissions and costs.SERA
Corporate presentation18 Mar 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation2 Mar 2026